Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding

Molecular Carcinogenesis

Volumn 25, Issue 3, 1999, Pages 219-229

  Kaltreider, Ronald C ^a   Pesce, Carrie A ^a   Ihnat, Michael A ^a   Lariviere, Jean P ^a   Hamilton, Joshua W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

AP 1; NF B; Sp1; Transcription factor; YB 1

Indexed keywords

ARSENIC; CHROMIUM;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CHEMICAL CARCINOGENESIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LD 50; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE ASSAY; RAT; TOXICITY; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0033033209     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199907)25:3<219::AID-MC8>3.0.CO;2-X     Document Type: Article

References (70)

1. Hayes RB. The carcinogenicity of metals in humans. Cancer Causes Control 1997;8:371-385.
2. French C, Peters W, Maxwell B, et al. Assessment of health risks due to hazardous air pollutant emissions from electric utilities. Drug Chem Toxicol 1997;20:375-386.
3. Mertz W. Risk assessment of essential trace elements: new approaches to setting recommended dietary allowances and safety limits. Nutr Rev 1995;53:179-185.
4. Hathcock JN. Safety limits for nutrients. J Nutr 1996;126: 2386S-2389S.
5. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997;13:291-298.
6. Bencko V. Arsenic. In: Fishbein L, Furst A, Mehlman MA, editors. Genotoxic and carcinogenic metals: Environmental and occupational occurrence and exposure. Princeton, NJ: Princeton Scientific Publishing, 1987. 1-30.
7. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 1998;147:660-669.
8. Cohen MD, Kargacin B, Klein CB, Costa M. Mechanisms of chromium carcinogenicity and toxicity. Crit Rev Toxicol 1993;23(3):255-281.
9. Alcedo JA, Misra M, Hamilton JW, Wetterhahn KE. The genotoxic carcinogen chromium(VI) alters the metal-inducible expression but not the basal expression of the metallothionein gene in vivo. Carcinogenesis 1994;15: 1089-1092.
10. Hamilton JW, Wetterhahn KE. Differential effects of chromium(VI) on constitutive and inducible gene expression in chick embryo liver in vivo and correlation with chromium(VI)-induced DNA damage. Mol Carcinog 1989;2: 274-286.
11. Hamilton JW, McCaffrey J, Caron RM, et al. Genotoxic chemical carcinogens target inducible genes in vivo. Ann N Y Acad Sci 1994;726:343-345.
12. McCaffrey J, Wolf CM, Hamilton JW. Effects of the genotoxic carcinogen chromium(VI) on basal and hormone-inducible phosphoenolpyruvate carboxykinase gene expression in vivo: Correlation with glucocorticoid- and developmentally regulated expression. Mol Carcinog 1994; 10:189-198.
13. Ihnat MA, Lariviere JP, Warren AJ, et al. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res 1997;3:1339-1346.
14. Hamilton JW, Kaltreider RC, Bajenova OV, et al. Molecular basis for effects of carcinogenic heavy metals on inducible gene expression. Environ Health Perspect 1998;106: 1005-1015.
15. Wetterhahn KE, Hamilton JW. Molecular basis of hexavalent chromium carcinogenicity: Effect on gene expression. Sci Total Environ 1989;86:113-129.
16. Wetterhahn KE, Hamilton JW, Aiyar J, Borges KM, Floyd R. Mechanism of chromium(VI) carcinogenesis. Reactive intermediates and effect on gene expression. Biol Trace Elem Res 1989;21:405-411.
17. Kim G, Yurkow EJ. Chromium induces a persistent activation of mitogen-activated protein kinases by redoxsensitive mechanism in H4 rat hepatoma cells. Cancer Res 1996;56:2045-2051.
18. Wiegand HJ, Ottenwalder H, Bolt HM. The reduction of chromium(VI) to chromium(III) by glutathione: An intercellular redox pathway in the metabolism of the carcinogen chromate. Toxicology 1984;33:341-348.
19. Kortenkamp A, Casadevall M, Faux SP, et al. A role for molecular oxygen in the formation of DNA damage during the reduction of the carcinogen chromium(VI) by glutathione. Arch Biochem Biophys 1996;329:199-207.
20. Chen F, Ye J, Zhang X, Rojanasakul Y, Shi X. One-electron reduction of chromium(VI) by alpha-lipoic acid and related hydroxyl radical generation, dG hydroxylation and nuclear transcription factor-kappa B activation. Arch Biochem Biophys 1997;338:165-172.
21. Davis CM, Sumrall KH, Vincent JB. A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Biochemistry 1996;35:12963-12969.
22. Ye J, Zhang X, Young HA, Mao Y, Shi X. Chromium(VI)-induced nuclear factor-kappa B activation in intact cells via free radical reactions. Carcinogenesis 1995;16:2401-2405.
23. Dong J, Luo X. Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 1994;315: 11-15.
24. Wang TS, Shu YF, Liu YC, Jan KY, Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 1997;121:229-237.
25. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 1996; 21:783-790.
26. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996;15:6269-6279.
27. Adcock IM. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 1997;52:178-186.
28. Thanos D, Maniatis T. NF-kappa B: A lesson in family values. Cell 1995;80:529-532.
29. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-1489.
30. Janssen YM, Barchowsky A, Treadwell M, Driscoll KE, Mossman BT. Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci USA 1995;92:8458-8462.
31. 2+ dependance, and differential half-site recognition. J Biol Chem 1991;266:252-260.
32. Read MA, Whitley MZ, Williams AJ, Collins T. NF-kB and IkBa: An inducible regulatory system in endothelial activation. J Exp Med 1994;179:503-512.
33. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 1988;85:7322-7326.
34. Spitkovsky DD, Royer-Pokora B, Delius H, et al. Tissue restricted expression and chromosomal localization of the YB-1 gene encoding a 42 kD nuclear CCAAT binding protein. Nucleic Acids Res 1992;20:797-803.
35. Kioka N, Tsubota J, Kakehi Y, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989;162: 224-231.
36. Finley BL, Kerger BD, Katona MW, Gargas ML, Corbett GC, Paustenbach DJ. Human ingestion of chromium(VI) in drinking water: pharmacokinetics following repeated exposure. Toxicol Appl Pharmacol 1997;142:151-159.
37. Gonsebatt ME, Vega L, Salazar AM, et al. Cytogenetic effects in human exposure to arsenic. Mutat Res 1997;386: 219-228.
38. Gianello G, Masco O, Carelli G, Vinci F, Castellino N. Occupational exposure to chromium - an assessment of environmental pollution levels and biological monitoring of exposed workers. Industrial Health 1998;36:74-77.
39. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997;66:581-611.
40. O'Brien RM, Noisin EL, Granner DK. Comparison of the effects of insulin and okadaic acid on phosphoenolpyruvate carboxykinase gene expression. Biochem J 1994;303: 737-742.
41. Sutherland C, Tebbey PW, Granner DK. Oxidative and chemical stress mimic insulin by selectively inhibiting the expression of phosphoenolpyruvate carboxykinase in hepatoma cells. Diabetes 1997;46:17-22.
42. McCaffrey J, Hamilton JW. Development regulation of basal and hormone-inducible phosphoenolpyruvate carboxykinase gene expression in chick embryo liver in vivo. Arch Biochem Biophys 1994;309:10-17.
43. Caron RM, Hamilton JW. Developmentally specific effects of the DNA cross-linking agent mitomycin C on phosphoenolpyruvate carboxykinase gene expression in vivo: Correlation with changes in chromatin structure within the promoter region of the gene. J Biochem Mol Toxicol 1998; 12:325-337.
44. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996;32A: 927-944.
45. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996;32A: 912-920.
46. Goldstein U. MDR1 gene expression in solid tumours. Eur J Cancer 1996;32A:1039-1050.
47. Silverman JA, Schrenk D. Hepatic canalicular membrane 4: Expression of the multidrug resistance genes in the liver. FASEB J 1997;11:308-313.
48. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
49. Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-394.
50. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996;56:4224-4228.
51. Karin M, Liu ZG, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246
52. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kb. Annu Rev Cell Biol 1994;10: 405-455.
53. Barchowsky A, Munro SR, Morana SJ, Vincenti MP, Treadwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa B and AP-1 in endothelial cells. Am J Physiol 1995;269:L829-L836.
54. Macleod D, Charlton J, Mullins J, Bird AP. Sp1 sites in the mouse Aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev 1994;8: 2282-2292.
55. Brandeis M, Frank D, Keshet I, et al. Sp1 elements protect a CpG island from de novo methylation. Nature 1994;371: 435-438.
56. Ammendola R, Mesuraca M, Russo T, Cimino F. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur J Biochem 1994;225:483-489.
57. Hunter T, Karin M. The regulation of transcription by phosphorylation. Cell 1992;70:375-387.
58. Leggett RW, Armstrong SA, Barry D, Mueller CR. Sp1 is phosphorylated and its DNA binding activity down-regulated upon terminal differentiation of the liver. J Biol Chem 1995;270:25879-25884.
59. Armstrong SA, Barry DA, Leggett RW, Mueller CR. Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J Biol Chem 1997;272: 13489-13495.
60. Goldsmith ME, Madden MJ, Morrow CS, Cowan KH. A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. J Biol Chem 1993;268:5856-5860.
61. Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447-450.
62. Wu X, Bishopric NH, Discher DJ, Murphy BJ, Webster KA. Physical and functional sensitivity of zinc finger transcription factors to redox change. Mol Cell Biol 1996;16: 1035-1046.
63. Sarkar B. Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation. Nutrition 1995;11: 646-649.
64. Predki PF, Sarkar B. Metal replacement in "zinc finger" and its effect on DNA binding. Environ Health Perspect 1994; 102 Suppl 3:195-198.
65. Nagaoka M, Kuwahara J, Sugiura Y. Alteration of DNA binding specificity by nickel (II) substitution in three zinc (II) fingers of transcription factor Sp1. Biochem Biophys Res Commun 1993;194:1515-1520.
66. Predki PF, Sarkar B. Effect of replacement of "zinc finger" zinc on estrogen receptor DNA interactions. J Biol Chem 1992;267:5842-5846.
67. Thiesen HJ, Bach C. Transition metals modulate DNA-protein interactions of SP1 zinc finger domains with its cognate target site. Biochem Biophys Res Commun 1991; 176:551-557.
68. Posewitz MC, Wilcox DE. Properties of the Sp1 zinc finger 3 peptide: Coordination chemistry, redox reactions, and metal binding competition with metallothionein. Chem Res Toxicol 1995;8:1020-1028.
69. Simons SS, Jr, Chakraborti PK, Cavanaugh AH. Arsenite and cadrnium(II) as probes of glucocorticoid receptor structure and function. J Biol Chem 1990;265:1938-1945.
70. Lopez S, Miyashita Y, Simons SS, Jr. Structurally based, selective interaction of arsenite with steroid receptors. J Biol Chem 1990;265:16039-16042.